Overview
NAGE market data
Price History
NAGE price chart
Valuation & Profitability
- P/E (TTM)
- 14.92 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.20 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.00 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 12.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.87 – $10.52 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $238.6M · P/B 6.63 · P/S 1.85.
Company News
Niagen Bioscience Announces Availability Of Its Healthy-Aging NAD+ Supplement Tru Niagen On Walmart.comBenzinga · Aug 6, 2026, 12:37 PM
Niagen Bioscience Says It Expects Full-Year Ingredient Business Below Prior Year As Commercial Partners Face More Competitive Market; Sees Niagen Plus And New Skincare Partnerships Contributing Beginning 2027Benzinga · Aug 4, 2026, 9:12 PM
Niagen Bioscience Widens FY2026 Sales Guidance of $138.982M-$145.299M vs $141.072M EstBenzinga · Aug 4, 2026, 8:06 PM
Niagen Bioscience Q2 EPS $0.01 Misses $0.02 Estimate, Sales $29.785M Miss $30.690M EstimateBenzinga · Aug 4, 2026, 8:03 PM
Niagen Bioscience Announces Selection Of Evotec As Contract Research Organization For IND-Enabling Studies Of NB4168 In Ataxia TelangiectasiaBenzinga · Aug 3, 2026, 12:35 PM
Aging Cell Publishes Study In 'Aging Cell' Showing Niagen NR Supplementation Reduces Muscle Biological Aging and Supports Healthy Muscle FunctionBenzinga · Jul 28, 2026, 12:34 PM
Niagen Bioscience Receives FDA Rare Pediatric Disease Designation For Its Drug Candidate NB4168 For The Treatment Of Ataxia TelangiectasiaBenzinga · Jul 13, 2026, 12:34 PM
Niagen Bioscience Files Prospectus To Offer And Sell Common Stock Up To $50MBenzinga · Jul 10, 2026, 9:20 PM
Niagen Bioscience Launches NAD Pharmaceuticals, Its Wholly Owned Subsidiary Focused On Developing Therapies For Accelerated Aging And Rare Genetic DiseasesBenzinga · Jul 8, 2026, 12:40 PM
Niagen Bioscience Officially Renames The ChromaDex External Research Program (CERP) To Niagen Research ProgramBenzinga · Jun 2, 2026, 12:45 PM